NCT03004495View on ClinicalTrials.gov

Pharmacokinetic Interaction and the Safety of Inhaled CHF5259 and CHF6001

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Copd
Interventions
DRUG

CHF5259 and CHF6001

b.i.d. for 14 days

DRUG

CHF5259 + placebo

b.i.d. for 14 days

DRUG

CHF6001 + placebo

b.i.d. for 14 days

OTHER

Placebo

b.i.d. for 14 days

Trial Locations (1)

SE1 1 YR

Quintiles CPU, London

All Listed Sponsors
collaborator

Quintiles, Inc.

INDUSTRY

lead

Chiesi Farmaceutici S.p.A.

INDUSTRY

NCT03004495 - Pharmacokinetic Interaction and the Safety of Inhaled CHF5259 and CHF6001 | Biotech Hunter | Biotech Hunter